Logo

LabCorp ADAMTS13 Test

Jul 19, 2017

Laboratory Corporation of America began offering the ADAMTS13 test for a rare life-threatening blood-clotting disorder. The test distinguishes diseases characterized by acute thrombotic microangiopathy (TMA), a relatively rare syndrome in which small blood vessels develop blood clots. The test can provide faster and more accurate results, compared to other tests, to rule in or out the diagnosis of thrombotic thrombocytopenia purpura, a condition that can cuase TMA, and to support decisions whether to start patients on certain therapies, LabCorp said. The test is run on liquid chromatography-tandem mass spectrometry technology.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.